Unmet Needs in the Treatment of Allergic Asthma: Potential Role of Novel Biologic Therapies

Storms, William W.

doi:10.18553/jmcp.2003.9.6.534

Cited by 8 publications

(5 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently available asthma therapies, although effective in the majority of patients, do not provide adequate asthma control in a substantial number of patients, require chronic dosing and have potential side effects, particularly at higher doses [31]. TLR7 agonists have potential as a new treatment option for allergic asthma through the stimulation of Th1/Th0 effector cells, thereby attenuating allergen-specific Th2 cells [15, 16].…”

Section: Discussionmentioning

confidence: 99%

Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study

et al. 2019

View full text Add to dashboard Cite

BackgroundAlthough allergic asthma is a complex area with many interacting factors involved, the ‘hygiene hypothesis’ proposes that a lack of exposure to infection during childhood may polarise the immune system towards allergen-reactive Th2-type responses in genetically susceptible individuals. Toll-like receptors (TLRs) play a key role within the innate immune system and TLR7 agonists have previously been shown to up-regulate Th1 responses and down-regulate Th2 responses to allergens in murine models of allergic or chronic asthma. This study aimed to examine the efficacy and safety of the novel TRL7 agonist AZD8848, which has been developed as an antedrug.MethodsIn this double-blind, randomised, parallel-group study, AZD8848 60 μg or placebo was administered intranasally once-weekly for 8 weeks in patients with mild-to-moderate allergic asthma (NCT00999466). Efficacy assessments were performed at 1 and 4 weeks after the last dose. The primary outcome was the late asthmatic response (LAR) fall in forced expiratory volume in 1 s (FEV1) after allergen challenge at 1-week post-treatment.ResultsAZD8848 significantly reduced average LAR fall in FEV1 by 27% vs. placebo at 1 week after treatment (p = 0.035). This effect was sustained at 4 weeks post-treatment; however, it did not reach clinical significance. AZD8848 reduced post-allergen challenge methacholine-induced airway hyper-responsiveness (AHR) vs. placebo at 1 week post-dosing (treatment ratio: 2.20, p = 0.024), with no effect at 4 weeks. There was no significant difference between the two groups in plasma cytokine, sputum Th2 cytokine or eosinophil responses post-allergen challenge at 1 week after treatment. The incidence of adverse events was similar in the two groups. AZD8848 was generally well tolerated.Conclusions and clinical relevanceIn patients with allergic asthma, TLR7 agonists could potentially reduce allergen responsiveness by stimulating Type 1 interferon responses to down-regulate the dominant Th2 responses.Trial registrationclinicaltrials.gov identifier NCT00999466.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…2 There are many patients whose symptoms are suboptimally controlled despite the use of multiple medications, including inhaled corticosteroids (ICSs), and the prevalence, morbidity, and mortality associated with asthma remain high. 3 A novel therapeutic approach with omalizumab, a recombinant humanized monoclonal anti-IgE antibody can reduce hospitalization and emergency department visits 4 and improve quality of life in patients with moderateto-severe, suboptimally controlled allergic asthma. But the magnitude of treatment effects does not seem to be as impressive as the remarkable reduction in circulating free IgE levels.…”

mentioning

confidence: 99%

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

Oba

Salzman

2004

Journal of Allergy and Clinical Immunology

119

View full text Add to dashboard Cite

“…68 A transition from purely dispensing medications to working directly with physicians and patients may have a favorable impact on patient disease outcomes and health care utilization. 69 Numerous studies have demonstrated a positive effect of pharmacist intervention on outcomes in adult patients with chronic diseases, including asthma. [70][71][72][73][74] In a 1-year pharmacybased intervention study carried out in community pharmacies throughout Denmark, 75 pharmacists counseled patients (aged 16 to 60 years) with asthma and reviewed patient inhaler technique on a monthly basis.…”

Section: Economic Value Of Pharmacy-based Interventionmentioning

confidence: 99%

Pediatric Asthma: Improving Management to Reduce Cost of Care

Mellon¹,

Parasuraman²

2004

JMCP

View full text Add to dashboard Cite

show abstract

Unmet Needs in the Treatment of Allergic Asthma: Potential Role of Novel Biologic Therapies

Cited by 8 publications

References 90 publications

Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study

Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

Pediatric Asthma: Improving Management to Reduce Cost of Care

Contact Info

Product

Resources

About